Gastro I., s.r.o.

Prešov 8001

5 studies enrolling now · 33 studies all time

What they study most

Colitis, Ulcerative, Crohn Disease, Crohn's Disease, Inflammatory Bowel Diseases, Moderately to Severely Active Crohn Disease, Ulcerative Colitis, Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

Studies at this site

• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — Recruiting now
• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Recruiting now
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• ABTECT - Maintenance — Running, not enrolling
• Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis — Stopped early
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis — Completed
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease — Completed
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies — Stopped early
• Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease — Stopped early
• Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease — Completed
• Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis — Completed
• Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis — Completed
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis — Completed
• A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease — Completed
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis — Completed
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors — Completed
• Efficacy and Safety Study of Ozanimod in Ulcerative Colitis — Completed
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis — Completed
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease — Stopped early
• A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease — Stopped early
• A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease — Completed
• An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis — Completed
• A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease — Withdrawn before enrolling
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis — Completed
• A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis — Completed